Side Effects of Medical Cancer Therapy: Prevention and Treatment

659 Pages·2013·3.94 MB·English

by  François Lokiec Ph.D., SciD (auth.), Mario A. Dicato (eds.)

Side Effects of Medical
Cancer Therapy

Mario A. Dicato
Editor
Side Effects of Medical
Cancer Therapy

Prevention and Treatment
Editor
M ario A. Dicato, M.D.
Department
of Hematology-Oncology
Centre Hospitalier
de Luxembourg
Luxembourg

ISBN 978-0-85729-786-0 ISBN 978-0-85729-787-7 (eBook)
DOI 10.1007/978-0-85729-787-7
Springer London Heidelberg New York Dordrecht
Library of Congress Control Number: 2012954609
© Springer-Verlag London 2013
This work is subject to copyright. All rights are reserved by the Publisher, whether
the whole or part of the material is concerned, speci fi cally the rights of translation,
reprinting, reuse of illustrations, recitation, broadcasting, reproduction on
micro fi lms or in any other physical way, and transmission or information storage
and retrieval, electronic adaptation, computer software, or by similar or dissimilar
methodology now known or hereafter developed. Exempted from this legal
reservation are brief excerpts in connection with reviews or scholarly analysis or
material supplied speci fi cally for the purpose of being entered and executed on
a computer system, for exclusive use by the purchaser of the work. Duplication
of this publication or parts thereof is permitted only under the provisions of the
Copyright Law of the Publisher’s location, in its current version, and permission
for use must always be obtained from Springer. Permissions for use may be
obtained through RightsLink at the Copyright Clearance Center. Violations are
liable to prosecution under the respective Copyright Law.
The use of general descriptive names, registered names, trademarks, service
marks, etc. in this publication does not imply, even in the absence of a speci fi c
statement, that such names are exempt from the relevant protective laws and
regulations and therefore free for general use.
While the advice and information in this book are believed to be true and
accurate at the date of publication, neither the authors nor the editors nor the
publisher can accept any legal responsibility for any errors or omissions that may
be made. The publisher makes no warranty, express or implied, with respect to
the material contained herein.
Printed on acid-free paper
Springer is part of Springer Science+Business Media (www.springer.com)
Preface
The reason for publishing a book on side effects of drugs
used in oncology is the fact that numerous new drugs, mostly
classifi e d as “targeted therapy,” have different and very varied
spectra of side effects. As standard chemotherapy drugs have
not changed much over the years in their adverse effect
pro fi les, oncologists are usually very familiar with these problems,
especially because over the past 20 years only a few new
chemotherapeutic drugs have been marketed.
Another aspect of oncology that has changed over the past
two decades is the fact that with the increase in life expec-
tancy, the median age at diagnosis of cancer has increased
and is presently around 70 years. Therefore, comorbidities
have become routine in oncological services, and many
patients are being treated with multiple medications for
other pathologies, which multiplies drug interactions and
compliance problems.
Targeted drugs have fl ooded the oncological literature,
and their spectrum of side effects is increasing, especially
since additional drugs become available every year and are
being used in several malignancies. This change of spectrum
of side effects is less and less organ-limited, and a physician
specialized in, for example, gastrointestinal malignancies is
now confronted with cardiac (trastuzumab in gastric cancer)
or dermatologic (EGFR inhibitor in colorectal cancer) toxicity.
Hence, in order to make it easy to look up a problem, overlaps
are unavoidable.
In putting together the layout of a book on side effects of
medical cancer therapy, several problems arose. Should the
side effects be grouped by organ, by drug, by type of toxicity,
v
vi Preface
or by other factors? A compromise needed to be found.
Therefore, the majority of the book is organ-oriented, with
the exception of chapters on pharmacogenetic-pharmacokinetic,
cardiac, dermatologic, and supportive care aspects.
I am grateful to the authors who spontaneously accepted
the task of writing their respective chapters. Though most of
them are prominent in their fi elds, many realized only later
that more than an update of a previously studied topic was
required and that they had to start anew. I thank them for
complying.
Special thanks to Diane Lamsback from Springer for her
untiring help in the preparation of this book.
Mario A. Dicato
Contents
1 Drug Interactions and Pharmacogenetics . . . . . . . . . . 1
François Lokiec
2 Breast Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 29
Philippe G. Aftimos, Andrea Gombos, Lina Pugliano,
Ahmad Awada, and Martine J. Piccart
3 Lung Cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 119
Stefan Zimmerman, Alessandra Curioni Fontecedro,
Rolf A. Stahel, and Solange Peters
4 Gastrointestinal Cancer: Selection of Clinically
Relevant Drug-Induced Toxicities Encountered
in Gastrointestinal Cancer Treatment . . . . . . . . . . . . . . . 139
Julie Bogaert, Pieter-Jan Cuyle,
and Eric Van Cutsem
5 Gynecologic Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
Sevilay Altintas, Dirk L.A.L. Schrijvers,
and Jan B. Vermorken
6 Genitourinary Cancer. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 247
Bertrand F. Tombal
7 Central Nervous System. . . . . . . . . . . . . . . . . . . . . . . . . . . 293
Miriame Mino, Krisztian Homicsko, and Roger Stupp
8 Bone Marrow Toxicity: Red Blood Cells. . . . . . . . . . . . . 333
Pere Gascon
vii
viii Contents
9 Bone Marrow Toxicity: White Blood Cells. . . . . . . . . . . 365
Matti S. Aapro
10 Dermatologic Side Effects of Systemic
Anticancer Therapy. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 381
Caroline Robert, Christina Mateus,
and Alexander M.M. Eggermont
11 Myeloid Malignancies. . . . . . . . . . . . . . . . . . . . . . . . . . . . . 421
Laurent Plawny
12 Lymphoma . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 447
Sigrid Cherrier-De Wilde
13 Multiple Myeloma. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 459
Mario A. Dicato
14 Preservation of Fertility in the Cancer Patient. . . . . . . . 465
Duhem Caroline and Fernand Ries
15 Cardiotoxicity. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 483
Irene Braña, Esther Zamora, and Josep Tabernero
16 Toxicity of Bone-Targeted Agents in Malignancy. . . . . 531
Caroline Wilson, Fiona G. Taylor,
and Robert E. Coleman
17 State of the Art of Antiemetic Therapy. . . . . . . . . . . . . . 569
Sonia Fatigoni and Fausto Roila
18 Side Effects of Nociceptive Cancer Pain
Treatments in Adults. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 595
Ivan Krakowski and Aline Henry
19 Totally Implanted Access Ports: Indications
and Prevention of Complications. . . . . . . . . . . . . . . . . . . 621
Didier S. Kamioner

Index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 635
Contributors
Matti S. Aapro , M.D. Department of Medical Oncology,
Institut Multidisciplinaire d’Oncologie, Clinique de
Genolier , Genolier , Switzerland
Philippe G. Aftimos , M.D. Medical Oncology Department,
Institut Jules Bordet, Université Libre de Bruxelles ,
Bruxelles , Belgium
Sevilay Altintas , M.D., Ph.D. Department of Medical
Oncology , Antwerp University Hospital , Edegem , Belgium
Ahmad Awada , M.D., Ph.D. Medical Oncology
Department , Institut Jules Bordet , Brussels , Belgium
Julie Bogaert , M.D. Department of Digestive Oncology ,
University Hospitals Gasthuisberg/Leuven , Leuven ,
Belgium
Irene Braña , M.D. Medical Oncology Department ,
Vall d’Hebron University Hospital , Barcelona , Spain
Sigrid Cherrier-De Wilde , M.D. Department of Hematology ,
Centre Hospitalier de Luxembourg , Luxembourg ,
Luxembourg
Robert E. Coleman , M.S., B.S., M.D., FRCP Academic Unit
of Clinical Oncology , Weston Park Hospital , Shef fi eld,
South Yorkshire , UK
ix